The Scottish Medicines Consortium has issued its monthly advice on new medicines.
Aliskiren (Rasilez®) has been rejected for the treatment of essential hypertension. Escitalopram (Cipralex®) has been rejected for the treatment of social anxiety disorder. Both rejections we made because the manufacturers failed to make a submission.
Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected medicines should be avoided.